Latest News

Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026. ImmunityBio Today’s Change (39.11%) $1.54

Keith Noonan, The Motley Fool January 16, 2026 at 4:38 PM Key Points CoreWeave stock trades at modest price-to-sales multiples compared to its growth.

It’s hard to escape economic news these days, even if you’re trying to. Headlines across all media are focused on the consumer price index,

It’s hard to beat Vanguard’s S&P 500 ETF. There are plenty of good exchange-traded funds (ETFs) costing less than $1,000 that will likely end

James Brumley, The Motley Fool January 16, 2026 at 12:05 PM Key Points Lingering inflation has forced most consumer goods companies to make unpopular

US stocks were little changed on Friday despite growing uncertainty over the next Fed chair, while strong bank earnings and ongoing geopolitical tensions capped

Chesnot / Getty Images: J. Countess / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content

Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be

Investors could get both high dividend yields and high returns with these stocks. Are high dividend yields joined at the hip with low share

WASHINGTON (Gray DC) – A Republican bill in the House to regulate congressional stock trading is moving forward as lawmakers face public pressure to